Mylan patents expiration
1. Denavir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6124304 | MYLAN | Penciclovir for the treatment of zoster associated pain |
Oct, 2014
(9 years ago) | |
| US5866581 | MYLAN | Penciclovir for the treatment of post therapeutic neuralgia |
Oct, 2014
(9 years ago) | |
| US5840763 | MYLAN | Treatment of a latent infection of herpes viruses |
Sep, 2015
(8 years ago) | |
| US5916893 | MYLAN | Treatment of a latent infection of herpes virus |
Sep, 2015
(8 years ago) | |
| US6469015 | MYLAN | Pharmaceutical formulation |
Oct, 2019
(4 years ago) | |
| US6579981 | MYLAN | Antiviral guanine derivatives |
Jun, 2020
(3 years ago) | |
Drugs and Companies using PENCICLOVIR ingredient
Market Authorisation Date: 24 September, 1996
Treatment: Treatment of recurrent herpes labialis (cold sores) in adults
Dosage: CREAM;TOPICAL
DENAVIR family patents
2. Ermeza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9345772 | MYLAN | Liquid levothyroxine formulations |
Feb, 2035
(10 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 29 April, 2022
Treatment: NA
Dosage: SOLUTION;ORAL
ERMEZA family patents
3. Evoclin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7374747 | MYLAN | Pharmaceutical foam |
Jan, 2024
(3 months ago) | |
| US7141237 | MYLAN | Pharmaceutical foam |
Feb, 2024
(2 months ago) | |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 22 October, 2004
Treatment: Treatment of acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
EVOCLIN family patents
4. Extina patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7553835 | MYLAN | Topical antifungal composition |
Oct, 2018
(5 years ago) | |
| US8026238 | MYLAN | Topical antifungal composition |
Oct, 2018
(5 years ago) | |
Drugs and Companies using KETOCONAZOLE ingredient
Market Authorisation Date: 12 June, 2007
Treatment: Treatment of seborrhea dermatitis in humans; Topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older
Dosage: AEROSOL, FOAM;TOPICAL
EXTINA family patents
5. Luxiq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126920 | MYLAN | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
Mar, 2016
(8 years ago) | |
| US7078058 | MYLAN | Corticosteroid-containing pharmaceutical composition |
May, 2017
(6 years ago) | |
Drugs and Companies using BETAMETHASONE VALERATE ingredient
Market Authorisation Date: 28 February, 1999
Treatment: Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
Dosage: AEROSOL, FOAM;TOPICAL
LUXIQ family patents
6. Olux patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126920 | MYLAN | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
Mar, 2016
(8 years ago) | |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 26 May, 2000
Treatment: Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
Dosage: AEROSOL, FOAM;TOPICAL
OLUX family patents
7. Olux E patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7029659 | MYLAN | Mousse composition |
Sep, 2019
(4 years ago) | |
| US6730288 | MYLAN | Mousse composition |
Sep, 2019
(4 years ago) | |
| US8962000 | MYLAN | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 4 months from now) | |
| US8460641 | MYLAN | Microemulsion process and composition |
Nov, 2028
(4 years from now) | |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 12 January, 2007
Treatment: Treatment of corticosteroid-responsive dermatoses
Dosage: AEROSOL, FOAM;TOPICAL
OLUX E family patents
8. Vusion patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147852 | MYLAN | Modified azole compounds as antifungal and antibacterial agents |
Mar, 2028
(3 years from now) | |
Drugs and Companies using MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE ingredient
Market Authorisation Date: 16 February, 2006
Treatment: Use for treatment of diaper dermatitis complicated by candidiasis
Dosage: OINTMENT;TOPICAL
VUSION family patents